SIGA Technologies/$SIGA
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About SIGA Technologies
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.
Ticker
$SIGA
Sector
Primary listing
Employees
46
Headquarters
Website
SIGA Metrics
BasicAdvanced
$468M
6.35
$1.03
0.97
$0.60
9.17%
Price and volume
Market cap
$468M
Beta
0.97
52-week high
$9.62
52-week low
$4.95
Average daily volume
386K
Dividend rate
$0.60
Financial strength
Current ratio
9.168
Quick ratio
7.022
Profitability
EBITDA (TTM)
90.836
Gross margin (TTM)
65.69%
Net profit margin (TTM)
43.23%
Operating margin (TTM)
52.42%
Effective tax rate (TTM)
23.17%
Revenue per employee (TTM)
$3,740,000
Management effectiveness
Return on assets (TTM)
26.43%
Return on equity (TTM)
39.94%
Valuation
Price to earnings (TTM)
6.349
Price to revenue (TTM)
2.714
Price to book
2.3
Price to tangible book (TTM)
2.31
Dividend yield (TTM)
9.17%
Growth
Revenue change (TTM)
-0.85%
Earnings per share change (TTM)
-13.82%
3-year revenue growth (CAGR)
-7.09%
10-year revenue growth (CAGR)
42.97%
3-year earnings per share growth (CAGR)
-10.83%
10-year earnings per share growth (CAGR)
3.69%
What the Analysts think about SIGA
Analyst ratings (Buy, Hold, Sell) for SIGA Technologies stock.
Bulls say / Bears say
Product revenue for the six months ended June 30, 2025, climbed to $84.9 million from $44.6 million a year earlier, driven by robust demand under U.S. government stockpile contracts (SEC 10-Q).
Net income for the first half of 2025 reached $35.1 million, up from $12.1 million in H1 2024, reflecting significant margin expansion and operating leverage (SEC 10-Q).
At June 30, 2025, SIGA reported $182.5 million in cash and cash equivalents with no debt, providing strong liquidity to support operations and growth initiatives (SEC 10-Q).
The EMA’s CHMP initiated an Article-20 referral for Tecovirimat-SIGA on July 25, 2025, after preliminary clinical trial results raised doubts about its effectiveness against mpox, creating risks that its EU marketing authorization could be revised or withdrawn (EMA).
Early data from the PALM007 and STOMP studies indicate Tecovirimat did not resolve mpox lesions faster than placebo, heightening regulatory concerns and casting doubt on TPOXX’s clinical value (EMA).
Roughly 93% of H1 2025 product revenue came from U.S. government BARDA contracts, leaving SIGA highly dependent on federal procurement and vulnerable to swings in government purchasing decisions (SEC 10-Q).
Data summarised monthly by Lightyear AI. Last updated on 5 Nov 2025.
SIGA Financial Performance
Revenues and expenses
SIGA Earnings Performance
Company profitability
SIGA News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for SIGA Technologies stock?
SIGA Technologies (SIGA) has a market cap of $468M as of November 08, 2025.
What is the P/E ratio for SIGA Technologies stock?
The price to earnings (P/E) ratio for SIGA Technologies (SIGA) stock is 6.35 as of November 08, 2025.
Does SIGA Technologies stock pay dividends?
Yes, the SIGA Technologies (SIGA) stock pays dividends to shareholders. As of November 08, 2025, the dividend rate is $0.6 and the yield is 9.17%. SIGA Technologies has a payout ratio of 0% on a trailing twelve-month basis.
When is the next SIGA Technologies dividend payment date?
The next SIGA Technologies (SIGA) dividend payment date is unconfirmed.
What is the beta indicator for SIGA Technologies?
SIGA Technologies (SIGA) has a beta rating of 0.97. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.